INFORMATION FOR 2014
WITH SUMMARIZED FINANCIAL
FOR THE YEAR ENDED DECEMBER 31, 2015

INTERNATIONAL FOUNDATION
Aplastic Anemia & MDS
FINANCIAL STATEMENTS
NOTES TO FINANCIAL STATEMENTS


EXHIBIT C - Statement of Functional Expenses, for the Year Ended December 31, 2015, with Summarized Financial Information for 2014.

EXHIBIT B - Statement of Activities and Change in Net Assets, for the Year Ended December 31, 2015, with Summarized Financial Information for 2014.


INDEPENDENT AUDITORS REPORT

PAGE NO.

CONTENTS

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
United States of America.

Cash flows for the year then ended in accordance with accounting principles generally accepted in the

United States of America.

In our opinion, the financial statements referred to above present fairly, in all material respects,

basis for our audit opinion.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a

significant change in accounting estimates made by management, as well as evaluating the overall presentation of

the financial statements.

We express no opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An auditor is also

auditors, the auditor considers internal control relevant to the

auditor’s judgment, the procedures specific depend on the auditor’s judgment.

Auditors’ Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We

presentation of financial statements. Any change from material misstatement, whether due to fraud or

Management’s Responsibility for the Financial Statements

experiences and cash flows for the year then ended, and the related notes to the financial statements.

December 31, 2015, and the related statements of changes in net assets, functional

Independent Auditors Report

We have audited the accompanying financial statements of the Foundation Inc., a not-for-profit organization.

To the Board of Directors

Annie Amanin, CFO

Ronald B. Dwyer

Freedman, Rosenberg

C有限责任会计师事务所

2016年年度审计师报告

我们审核了附注中披露的财务信息。
June 21, 2016

Georgia Hanley & Associates

which it has been derived.

December 31, 2014, is consistent in all material respects with the audited financial statements from
December 31, 2014, is consistent in all material respects with the audited financial statements from
December 31, 2014, is consistent in all material respects with the audited financial statements from
December 31, 2014, is consistent in all material respects with the audited financial statements from

The summarized comparative information presented herein as of and for the year ended
The summarized comparative information presented herein as of and for the year ended
The summarized comparative information presented herein as of and for the year ended
The summarized comparative information presented herein as of and for the year ended

We have previously audited the Foundation's 2014 financial statements, and we expressed an
We have previously audited the Foundation's 2014 financial statements, and we expressed an
We have previously audited the Foundation's 2014 financial statements, and we expressed an
We have previously audited the Foundation's 2014 financial statements, and we expressed an

Report on Summarized Comparative Information
Report on Summarized Comparative Information
Report on Summarized Comparative Information
Report on Summarized Comparative Information
See accompanying notes to financial statements.

### Total Liabilities and Net Assets

<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2,487,901</td>
<td>Total net assets</td>
</tr>
<tr>
<td>$6,328,594</td>
<td>Temporarily restricted</td>
</tr>
<tr>
<td>$4,734,726</td>
<td>Total unrestricted</td>
</tr>
<tr>
<td>$403,749</td>
<td>Board-designated</td>
</tr>
<tr>
<td>$227,912</td>
<td>Undesignated</td>
</tr>
<tr>
<td>$126,230</td>
<td>Unrestricted</td>
</tr>
<tr>
<td>$1,313,084</td>
<td>Total current liabilities</td>
</tr>
<tr>
<td>$1,441,714</td>
<td>Grants payable</td>
</tr>
<tr>
<td>$493,891</td>
<td>Accounts receivable</td>
</tr>
<tr>
<td>$352,722</td>
<td>Accounts payable</td>
</tr>
</tbody>
</table>

### Current Liabilities

### Total Assets

<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>$6,287,901</td>
<td>Total other assets</td>
</tr>
<tr>
<td>$2,487,901</td>
<td>Charitable Remainder Trust</td>
</tr>
<tr>
<td>$260,755</td>
<td>Security deposits</td>
</tr>
<tr>
<td>$2,340,090</td>
<td>Net fixed assets</td>
</tr>
<tr>
<td>$10,541</td>
<td>Less: accumulated depreciation</td>
</tr>
<tr>
<td>$914,062</td>
<td>Property and equipment</td>
</tr>
<tr>
<td>$2,271,714</td>
<td>Fixed assets</td>
</tr>
<tr>
<td>$7,081,388</td>
<td>Total current assets</td>
</tr>
<tr>
<td>$1,157,469</td>
<td>Prepaid expenses</td>
</tr>
<tr>
<td>$2,264,745</td>
<td>Inventory</td>
</tr>
<tr>
<td>$2,264,745</td>
<td>Contributions and grants receivable</td>
</tr>
<tr>
<td>$3,784,609</td>
<td>Investments</td>
</tr>
<tr>
<td>$1,707,562</td>
<td>Cash and cash equivalents</td>
</tr>
</tbody>
</table>

### Current Assets

### Assets

WITH SUMMARYIZED FINANCIAL INFORMATION FOR 2014
AS OF DECEMBER 31, 2015
STATEMENT OF FINANCIAL POSITION
APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.

EXHIBIT A
<table>
<thead>
<tr>
<th>NET ASSETS AT END OF YEAR</th>
<th>Change in net assets</th>
<th>Total expenses</th>
<th>Supporting Services</th>
<th>General and Administrative Expenses</th>
<th>Program Services</th>
<th>Total Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ 6,105.91</td>
<td>$ 6,935.097</td>
<td>7,700.74</td>
<td>7,880.349</td>
<td>6,886.998</td>
<td>949.698</td>
<td></td>
</tr>
<tr>
<td>6,106.91</td>
<td>6,936.022</td>
<td>(6,933.808)</td>
<td>(6,944.371)</td>
<td>(6,377.63)</td>
<td>(479.312)</td>
<td></td>
</tr>
<tr>
<td>5,158.43</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$ 4,471.782</td>
<td>$ 4,325.093</td>
<td>$ 402.732</td>
<td>$ 963.986</td>
<td>$ 760.305</td>
<td>$ 5,925.283</td>
<td></td>
</tr>
<tr>
<td>4,472.782</td>
<td>4,326.093</td>
<td>402.732</td>
<td>964.986</td>
<td>760.305</td>
<td>5,925.283</td>
<td></td>
</tr>
<tr>
<td>3,415.228</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5,825.293</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**EXHIBIT B**

Statements of Activities and Change in Net Assets of Aplastic Anemia & MDS International Foundation, Inc.

**Statement with Summarized Financial Information for 2014**

**For the Year Ended December 31, 2014**

**Revenues**

<table>
<thead>
<tr>
<th>Temporary Restricted</th>
<th>Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ 141,472</td>
<td>$ 17,923</td>
<td>$ 159,395</td>
</tr>
</tbody>
</table>

**Expenses**

<table>
<thead>
<tr>
<th>Temporary Restricted</th>
<th>Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ 77,592</td>
<td>$ 3,923</td>
<td>$ 81,515</td>
</tr>
</tbody>
</table>

**Revenues**

- Total Revenue
  - Net assets released from donor
  - Conference and other revenue
  - Royalty income
  - Contributed materials
  - Investment (loss) income
  - Trust and wills
  - Special events
  - Fundraising
  - Corporate and other
  - Individuals
  - Contributions and grants

**Restricted**

- Total Restricted
- Temporary Restricted
- Restricted

**2014**

- Total
- Restricted
- Temporary Restricted
- 2015
The table below shows the expenses for various categories for the years 2014 and 2015.

<table>
<thead>
<tr>
<th>Category</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administrative Service Expenses</td>
<td>$12,050</td>
<td>$15,500</td>
</tr>
<tr>
<td>General and Program Services</td>
<td>$2,750</td>
<td>$3,250</td>
</tr>
<tr>
<td>Total</td>
<td>$14,800</td>
<td>$18,750</td>
</tr>
</tbody>
</table>

With summarized financial information for 2014 for the year ended December 31, 2014.

Statement of Functional Expenses

Aplastic Anemia & MDS International Foundation, Inc.
<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash flows from operating activities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$1,378,125</td>
<td>$170,874</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash provided (used) by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation</td>
<td>59,360</td>
<td>62,572</td>
</tr>
<tr>
<td>Unrealized losses on investments</td>
<td>310,843</td>
<td>70,000</td>
</tr>
<tr>
<td>Realized gains on investments</td>
<td>(92,474)</td>
<td>(183,010)</td>
</tr>
<tr>
<td>Donated investments</td>
<td>(4,727)</td>
<td>(4,213)</td>
</tr>
<tr>
<td>Change in value of Charitable Remainder Trust</td>
<td>(11,352)</td>
<td>(10,712)</td>
</tr>
<tr>
<td>(Increase) decrease in:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions and grants receivable</td>
<td>1,531,818</td>
<td>1,071,273</td>
</tr>
<tr>
<td>Inventory</td>
<td>2,648</td>
<td>1,060</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>(11,352)</td>
<td>(10,712)</td>
</tr>
<tr>
<td>Increase (decrease) in:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable</td>
<td>853</td>
<td>258,332</td>
</tr>
<tr>
<td>Accrued expenses</td>
<td>(376,538)</td>
<td>139,694</td>
</tr>
<tr>
<td>Grants payable</td>
<td>622,718</td>
<td>(835,221)</td>
</tr>
<tr>
<td>Net cash provided (used) by operating activities</td>
<td>545,205</td>
<td>(1,537,532)</td>
</tr>
<tr>
<td>Cash flows from investing activities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net (purchase) sales of investments</td>
<td>(2,86,953)</td>
<td>(2,86,953)</td>
</tr>
<tr>
<td>Purchase of property and equipment</td>
<td>(4,457)</td>
<td>(4,457)</td>
</tr>
<tr>
<td>Net cash provided (used) by investing activities</td>
<td>(2,86,410)</td>
<td>(2,86,957)</td>
</tr>
<tr>
<td>Net increase (decrease) in cash and cash equivalents at beginning of year</td>
<td>2,92,795</td>
<td>1,059,245</td>
</tr>
<tr>
<td>Cash and cash equivalents at end of year</td>
<td>1,297,502</td>
<td>1,059,245</td>
</tr>
</tbody>
</table>

See accompanying notes to financial statements.
seven years. The cost of maintenance and repair is recorded as expenses are incurred.

Fixed assets with acquisition costs of $500 or more are stated at cost and depreciated using the
straight-line method over the estimated useful lives of the related assets. Generally, a useful life is
assumed to be 10 years for buildings, 8 years for furniture and equipment, and 5 years for

- Fixed assets


debt service.

Contributions and grants receivable and other amounts due from financial institutions are not
considered to be fully collectable. Accordingly, an allowance for doubtful accounts has been
established. All contributions and grants receivable are reduced by an amount that reflects
management's estimate of the probability of collectability.

- Contributions and grants receivable

Investments

Inventories are recorded at their readily determinable fair value, less estimated costs of
completion and disposition.

- Inventories

Risk Management

The foundation maintains cash balances at financial institutions in

- Investments

The foundation considers all cash and other highly liquid investments with initial maturities of

- Cash and cash equivalents

basis of presentation

- Organization

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION

DECEMBER 31, 2015
NOTES TO FINANCIAL STATEMENTS

APLASTIC ANEMIA & MULTIPLE MYELOMA INTERNATIONAL FOUNDATION, INC.


Accordingly, actual results could differ from those estimated.

Statements and the reported amounts of revenue and expenses during the reporting period.

Assumptions that affect the reported amounts of assets and liabilities at the date of the financial
statements in the United States of America, Management to make estimates and
accord with accounting principles generally

The preparation of the financial statements is in accordance with accounting

- Use of estimates

- Contributions and grants

- Net assets released from restrictions

- Temporarily restricted net assets

- Unrestricted net assets

The net assets are reported in two self-balancing groups as follows:

- Net asset classification

- Uncertain tax positions

- Income taxes

- Contributed materials (continued)

(continued)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION

DECEMBER 31, 2015
NOTES TO FINANCIAL STATEMENTS

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
TOTAL INVESTMENT LOSS

Realized gain
Unrealized loss
Interest, dividends, and fees

Included in investment loss are the following for the year ended December 31, 2016:

$ 155,316

TOTAL INVESTMENTS

Mutual funds
Common stock
Corporate bonds
U.S. Treasury notes and government agency securities

Market Value

Investments consisted of the following as of December 31, 2015:

2. INVESTMENTS

For a significant portion of its financial instruments at fair value or considered fair value in their measurement, the Foundation accounts and discloses investments using the fair value measurement model. The provisions of FASB ASC 820, "Fair Value Measurement," were adopted by the Foundation. ASC 820 defines fair value, establishes a framework for measuring fair value, and establishes a fair value hierarchy based on the quality of available inputs. The hierarchy reflects the quality of inputs used in the valuation of assets and liabilities, including assumptions about market risk (assumptions that market participants would use in pricing assets or liabilities).

The guidance establishes a fair value hierarchy for disclosure purposes, as described below:

Level 1 - fair value measurement in the accompanying financial statements, the market price of an identical instrument or an instrument with similar characteristics and risks.

Level 2 - fair value measurement in which all significant inputs other than quoted prices in active markets for identical assets or liabilities (Level 1) are observable, or can be corroborated by observable market data for substantially the same instrument.

Level 3 - fair value measurement in which significant unobservable inputs that reflect management's best estimate of what market participants would use in pricing assets or liabilities.

Risks and uncertainties

The Foundation invests in various investment securities. Investment securities are exposed to various risks such as interest rates, market and credit risks. These risks may affect the values of the Foundation's investments. The Foundation has adopted the provisions of FASB ASC 820, "Fair Value Measurement," which establishes a framework for measuring fair value and establishes a fair value hierarchy for disclosure purposes.

- Functional allocation of expenses

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION

DECEMBER 31, 2016
NOTES TO FINANCIAL STATEMENTS
APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
6. CHARITABLE REMAINDER TRUST

Year Ending December 31, 2016

Future minimum payments are as follows:

Total real estate was $129,875. For the year ended December 31, 2015, and is included in

Total annual expenses was $131,916. The expenses will expire on December 31, 2016.

In October 2016, the Foundation entered into a lease agreement for additional office space by signing an additional lease for

5. LEASE COMMITMENT

<table>
<thead>
<tr>
<th>TOTAL NET ASSETS RELEASED FROM DONOR RESTRICTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4,200,674</td>
</tr>
<tr>
<td>200,000</td>
</tr>
<tr>
<td>9,700</td>
</tr>
<tr>
<td>14,916</td>
</tr>
<tr>
<td>2,903,920</td>
</tr>
<tr>
<td>6,949,038</td>
</tr>
</tbody>
</table>

The following temporarily restricted net assets were released from donor restrictions for the year ended December 31, 2016:

<table>
<thead>
<tr>
<th>TOTAL TEMPORARILY RESTRICTED NET ASSETS</th>
</tr>
</thead>
<tbody>
<tr>
<td>$260,224</td>
</tr>
<tr>
<td>626,987</td>
</tr>
<tr>
<td>315,000</td>
</tr>
<tr>
<td>135,985</td>
</tr>
<tr>
<td>12,894,985</td>
</tr>
<tr>
<td>1,261,850</td>
</tr>
</tbody>
</table>

Temporary restricted net assets consisted of the following at December 31, 2016:

NOTES TO FINANCIAL STATEMENTS

APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.
The table below summarizes, by level within the fair value hierarchy, the Foundation’s investments as of December 31, 2015. Fifteen different fair value categories are presented here. The table includes both financial assets and non-financial assets. The fair value hierarchy is based on a market approach, which maximizes the use of market prices and minimizes the use of non-market inputs.

<table>
<thead>
<tr>
<th>Description</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>良用 fund investments</td>
<td>2,394,006</td>
<td>-</td>
<td>-</td>
<td>2,394,006</td>
</tr>
<tr>
<td>Principal investments</td>
<td>1,166,005</td>
<td>-</td>
<td>-</td>
<td>1,166,005</td>
</tr>
<tr>
<td>Common stock investments</td>
<td>1,659,999</td>
<td>-</td>
<td>-</td>
<td>1,659,999</td>
</tr>
<tr>
<td>Total</td>
<td>4,219,000</td>
<td>-</td>
<td>-</td>
<td>4,219,000</td>
</tr>
</tbody>
</table>

# Fair Value Measurement

The fair value hierarchy is as follows:

- **Level 1**: Fair values are quoted and active market prices are available for identical instruments.
- **Level 2**: Fair values are based on quoted market prices for similar instruments, quoted prices for identical or similar instruments in inactive markets, model-derived valuations, or other valuation techniques.
- **Level 3**: Fair values are based on unobservable inputs and are used to measure investments that are not traded or valued in inactive markets.

The fair value hierarchy for each major class of investment is as follows:

- **Charitable Remainder Trusts**: Level 1 ($2,394,006)
- **Principal Investments**: Level 2 ($1,166,005)
- **Common Stock Investments**: Level 2 ($1,659,999)

The fair value hierarchy is based on a market approach, which maximizes the use of market prices and minimizes the use of non-market inputs. The fair values are based on quoted market prices for identical instruments in active markets.

The fair value measurement is based on the lowest level input (i.e., Level 3) in the hierarchy of liquid inputs (Level 2) and the lowest quantity of non-liquid (Level 3) inputs.

The fair value hierarchy gives the highest priority to quoted prices in active markets. The fair value of investments, based on the priority of inputs, is as follows:

- **Charitable Remainder Trusts**: Level 3 ($2,394,006)
- **Principal Investments**: Level 3 ($1,166,005)
- **Common Stock Investments**: Level 3 ($1,659,999)

The fair values are based on quoted market prices for identical instruments in active markets.

The fair value measurement is based on the lowest level input (i.e., Level 3) in the hierarchy of liquid inputs (Level 2) and the lowest quantity of non-liquid (Level 3) inputs.

The fair value hierarchy gives the highest priority to quoted prices in active markets. The fair value of investments, based on the priority of inputs, is as follows:

- **Charitable Remainder Trusts**: Level 3 ($2,394,006)
- **Principal Investments**: Level 3 ($1,166,005)
- **Common Stock Investments**: Level 3 ($1,659,999)

The fair values are based on quoted market prices for identical instruments in active markets.

The fair value measurement is based on the lowest level input (i.e., Level 3) in the hierarchy of liquid inputs (Level 2) and the lowest quantity of non-liquid (Level 3) inputs.

The fair value hierarchy gives the highest priority to quoted prices in active markets. The fair value of investments, based on the priority of inputs, is as follows:

- **Charitable Remainder Trusts**: Level 3 ($2,394,006)
- **Principal Investments**: Level 3 ($1,166,005)
- **Common Stock Investments**: Level 3 ($1,659,999)

The fair values are based on quoted market prices for identical instruments in active markets.

The fair value measurement is based on the lowest level input (i.e., Level 3) in the hierarchy of liquid inputs (Level 2) and the lowest quantity of non-liquid (Level 3) inputs.

The fair value hierarchy gives the highest priority to quoted prices in active markets. The fair value of investments, based on the priority of inputs, is as follows:

- **Charitable Remainder Trusts**: Level 3 ($2,394,006)
- **Principal Investments**: Level 3 ($1,166,005)
- **Common Stock Investments**: Level 3 ($1,659,999)

The fair values are based on quoted market prices for identical instruments in active markets.

The fair value measurement is based on the lowest level input (i.e., Level 3) in the hierarchy of liquid inputs (Level 2) and the lowest quantity of non-liquid (Level 3) inputs.

The fair value hierarchy gives the highest priority to quoted prices in active markets. The fair value of investments, based on the priority of inputs, is as follows:

- **Charitable Remainder Trusts**: Level 3 ($2,394,006)
- **Principal Investments**: Level 3 ($1,166,005)
- **Common Stock Investments**: Level 3 ($1,659,999)

The fair values are based on quoted market prices for identical instruments in active markets.

The fair value measurement is based on the lowest level input (i.e., Level 3) in the hierarchy of liquid inputs (Level 2) and the lowest quantity of non-liquid (Level 3) inputs.

The fair value hierarchy gives the highest priority to quoted prices in active markets. The fair value of investments, based on the priority of inputs, is as follows:

- **Charitable Remainder Trusts**: Level 3 ($2,394,006)
- **Principal Investments**: Level 3 ($1,166,005)
- **Common Stock Investments**: Level 3 ($1,659,999)

The fair values are based on quoted market prices for identical instruments in active markets.
In preparing these financial statements, the Foundation has evaluated events and transactions for potential recognition or disclosure through June 30, 2016. The date the financial statements were issued.

9. SUBSEQUENT EVENTS

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>31.1.2016</td>
<td>Present Value Appropriation</td>
<td>$290,224</td>
</tr>
<tr>
<td>1.16</td>
<td>Balance as of December 31, 2015</td>
<td>14,164</td>
</tr>
<tr>
<td></td>
<td>Balance as of December 31, 2014</td>
<td>239,060</td>
</tr>
</tbody>
</table>

The following table provides a summary of changes in fair value of the Foundation's financial assets for the year ended December 31, 2015:

The change in present value is recorded in permanently restricted net assets and is associated with the charitable remainder trust, which is still held at December 31, 2015.

8. FAIR VALUE MEASUREMENT (continued)

DECEMBER 31, 2015
NOTES TO FINANCIAL STATEMENTS
APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION, INC.